53.24
0.74 (1.42%)
| Previous Close | 52.49 |
| Open | 52.85 |
| Volume | 522,983 |
| Avg. Volume (3M) | 1,034,127 |
| Market Cap | 2,922,164,992 |
| Price / Sales | 12.92 |
| Price / Book | 8.62 |
| 52 Weeks Range | |
| Earnings Date | 25 Feb 2025 |
| Profit Margin | -36.20% |
| Operating Margin (TTM) | -39.67% |
| Diluted EPS (TTM) | -1.67 |
| Quarterly Revenue Growth (YOY) | 55.30% |
| Total Debt/Equity (MRQ) | 21.02% |
| Current Ratio (MRQ) | 8.95 |
| Operating Cash Flow (TTM) | -83.91 M |
| Levered Free Cash Flow (TTM) | -58.77 M |
| Return on Assets (TTM) | -13.36% |
| Return on Equity (TTM) | -27.62% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Bearish | Mixed |
| Medical Devices (Global) | Bearish | Mixed | |
| Stock | PROCEPT BioRobotics Corporation | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | 0.0 |
| Price Volatility | 4.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.00 |
|
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System,, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 4.20% |
| % Held by Institutions | 92.97% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 84.00 (B of A Securities, 57.79%) | Buy |
| Median | 77.00 (44.64%) | |
| Low | 70.00 (Truist Securities, 31.49%) | Buy |
| Average | 77.00 (44.64%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 52.28 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B of A Securities | 25 Apr 2025 | 84.00 (57.79%) | Buy | 52.49 |
| Truist Securities | 11 Apr 2025 | 70.00 (31.49%) | Buy | 52.07 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| DODRILL AMY M. | 64.23 | - | 1,538 | 98,786 |
| GARRETT MARY | 64.23 | - | 1,538 | 98,786 |
| HARRIS TAYLOR C. | 64.23 | - | 1,538 | 98,786 |
| MOLL FREDERIC H | 64.23 | - | 1,538 | 98,786 |
| PRESCOTT THOMAS M | 64.23 | - | 1,538 | 98,786 |
| SANDOVAL ELISABETH | 64.23 | - | 1,538 | 98,786 |
| WOOD LARRY L | 64.23 | - | 1,538 | 98,786 |
| Aggregate Net Quantity | 10,766 | |||
| Aggregate Net Value ($) | 691,500 | |||
| Aggregate Avg. Buy ($) | 64.23 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| PRESCOTT THOMAS M | Director | 10 Jun 2025 | Acquired (+) | 1,538 | 64.23 | 98,786 |
| DODRILL AMY M. | Director | 10 Jun 2025 | Acquired (+) | 1,538 | 64.23 | 98,786 |
| GARRETT MARY | Director | 10 Jun 2025 | Acquired (+) | 1,538 | 64.23 | 98,786 |
| HARRIS TAYLOR C. | Director | 10 Jun 2025 | Acquired (+) | 1,538 | 64.23 | 98,786 |
| WOOD LARRY L | Director | 10 Jun 2025 | Acquired (+) | 1,538 | 64.23 | 98,786 |
| SANDOVAL ELISABETH | Director | 10 Jun 2025 | Acquired (+) | 1,538 | 64.23 | 98,786 |
| MOLL FREDERIC H | Director | 10 Jun 2025 | Acquired (+) | 1,538 | 64.23 | 98,786 |
| Date | Type | Details |
|---|---|---|
| 29 Apr 2025 | Announcement | PROCEPT BioRobotics® to Attend Four Upcoming Investor Conferences in May & June |
| 24 Apr 2025 | Announcement | PROCEPT BioRobotics Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance |
| 24 Apr 2025 | Announcement | PROCEPT BioRobotics' Aquablation Therapy Spotlighted at 2025 AUA Annual Meeting Along with Expert-Led Workshops |
| 10 Apr 2025 | Announcement | PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting at the Aria Resort in Las Vegas |
| 24 Mar 2025 | Announcement | WATER III Randomized-Controlled Trial Results Announced at European Association of Urology Comparing Aquablation® Therapy to Laser Enucleation |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |